8-K: Catheter Precision Reports 135% Q3 Revenue Surge

Catheter Precision announced a 135% increase in Q3 2025 revenue, driven by international expansion of its LockeT and VIVO product lines.

Summary

• Total revenue for Q3 2025 was $226,000, marking a 135% increase compared with $96,000 in Q3 2024.
• Total revenue for the nine months ended September 30, 2025, reached $581,000, an increase of 114% from $271,000 in the same period of 2024.
• GAAP net loss for Q3 2025 was $2,251,000, representing a 45% reduction compared to $4,120,000 in Q3 2024.
• GAAP net loss for the nine months ended September 30, 2025, was $11,405,000, compared to $11,015,000 for the same period in 2024.
• Non-cash charges for the nine months ended September 30, 2025, and 2024 were $4,232,000 and $4,437,000, respectively.
• Sales activities for LockeT are increasing outside the United States, with CE Mark approval generating interest in Germany, France, Italy, Spain, Portugal, UK, and South Africa.
• Five accounts in South Africa placed reorders for LockeT in October 2025.
• Sales activity for VIVO is gaining traction internationally, including the first purchase order from France in October 2025.
• Two VIVO clinical studies were completed in 2025, delivering powerful clinical evidence.
• EP Lab Digest, a recognized publication, featured an interview highlighting the use and economic benefits of the LockeT suture retention device.

Sentiment

Score: 6

Explanation: The company demonstrated substantial revenue growth and a notable reduction in its Q3 net loss, indicating positive operational momentum and market acceptance for its products. However, the persistent overall net loss, low cash position, and explicit 'going concern' warning, coupled with the risk of significant shareholder dilution and potential delisting, present considerable financial challenges and risks.

Positives

• Significant revenue growth: 135% increase in Q3 2025 revenue ($226,000) compared to Q3 2024 ($96,000).
• Strong year-to-date revenue growth: 114% increase for the nine months ended September 30, 2025 ($581,000) compared to the same period in 2024 ($271,000).
• Reduced Q3 net loss: 45% reduction in GAAP net loss for Q3 2025 ($2,251,000) compared to Q3 2024 ($4,120,000).
• International expansion: LockeT received CE Mark approval and is generating interest and reorders in multiple European and African countries.
• VIVO product line gaining international traction, with a first purchase order from France.
• Completion of two VIVO clinical studies in 2025, providing powerful clinical evidence.
• Positive industry recognition through an interview in EP Lab Digest highlighting LockeT's benefits.

Negatives

• Continued net loss: GAAP net loss for the nine months ended September 30, 2025, was $11,405,000, an increase from $11,015,000 in the same period of 2024.
• Low cash position and the requirement to raise additional funds to finance operations and continue as a going concern.
• Risk of significant dilution to existing stockholders if additional funds are raised.
• Stockholder equity is near the minimum level prescribed by the NYSE American, risking delisting.
• History of losses and expectation of additional losses, with no guarantee of achieving profitability.
• Identified material weaknesses in internal control over financial reporting.
• Reliance on third parties for clinical trials and component supply.
• Highly competitive industry with competitors having substantially greater resources.

Risks

• Pursuing a strategic transaction, such as a crypto treasury strategy, may change the primary focus of the business and divert management from core operations and regulatory approvals.
• Results of anticipated trials may not meet expectations, and future trials may not occur on expected timelines, be more costly, or be abandoned due to lack of financing or changes in business focus.
• The current cash position is low, and the company will be required to raise additional funds to finance operations and continue as a going concern.
• There is no guarantee that the company will be able to raise necessary funds when required, and/or the terms of any financings may not be advantageous or could require changes to governance or operations.
• The company may require additional funds sooner than current expectations and may be required to significantly dilute existing stockholders to raise sufficient operating funds, assuming funds can be raised at all.
• Stockholder equity is near the minimum level prescribed by the NYSE American, and failure to maintain minimum listing requirements could lead to delisting.
• Common stock may be subject to extreme market volatility and trading patterns, experiencing rapid and substantial increases or decreases unrelated to operating performance or prospects.
• The operating business has a history of losses, is expected to incur additional losses, and may never achieve profitability.
• Past performance may not be a reliable indicator of future performance, including in the event of a strategic transaction.
• Historical trends should not be used to anticipate results or trends in future periods.
• The ability to increase at-the-market offering availability in the future is subject to obtaining necessary approvals, certifications, legal opinions, and accounting comfort letters, with no guarantee of success.
• Material weaknesses have been identified in internal control over financial reporting, which could adversely affect the ability to report results of operations and financial condition accurately and timely.
• Compliance with Sarbanes-Oxley Act Section 404 could have a material adverse impact on the business.
• Profitability will not be achieved unless product expansion and growth goals are met or a strategic transaction realigns the business focus.
• VIVO launch plans require significant investment in infrastructure and sales representatives.
• Research and development and commercialization efforts may depend on entering into agreements with corporate collaborators.
• Joint marketing agreements with respect to products will reduce revenues from product sales.
• Royalty agreements with respect to LockeT will reduce any future profits from this product.
• Significant disruptions in information technology systems could adversely affect the business.
• Litigation and other legal proceedings may adversely affect the business.
• Acquisitions or divestitures could lead to difficulties that harm the business, and entering into a strategic transaction could materially alter the business model and focus.
• Failure to attract and retain sufficient qualified personnel could impede growth.
• Revenues may depend on customers' receipt of adequate reimbursement from private insurers and government-sponsored healthcare programs.
• The company may be unable to compete successfully with companies in its highly competitive industry, many of whom have substantially greater resources.
• Future operating results depend upon the ability to obtain components in sufficient quantities on commercially reasonable terms or according to acceptable schedules, prices, quality, and volumes.
• If hospitals, physicians, and patients do not accept current and future products, or if the market for indications is smaller than expected, the company may be unable to generate significant operating revenue.
• The recent coronavirus outbreak (COVID-19) adversely affected financial condition and results of operations, and future impacts from COVID-19 or another pandemic are uncertain.
• A variety of risks associated with marketing products internationally could materially adversely affect the business.
• The impact of military conflicts in Ukraine and Israel, and actions taken by other countries, have affected and may continue to affect the business and results of operations, including the supply chain.
• If third parties relied upon for clinical trials do not perform activities in accordance with good clinical practices and regulatory requirements, regulatory approval or commercialization of product candidates may be hindered.
• The company may be adversely affected by product liability claims, unfavorable court decisions, or legal settlements.
• The ability to use net operating loss carryforwards may be limited.
• The company is subject to pervasive and continuing regulation by the FDA and other regulatory agencies.
• Products may be subject to additional recalls, revocations, or suspensions after receiving FDA or foreign approval or clearance, which could divert resources, harm reputation, and adversely affect the business.
• Changes in trade policies among the U.S. and other countries, particularly new or higher tariffs, could place pressure on average selling prices and have a material adverse effect on revenues and operating results.
• Product clearances and approvals can often be denied or significantly delayed.
• Expanding uses for products, if implemented, would require additional clearances, even after initial regulatory clearance.
• Even after clearance is obtained, products remain subject to extensive regulatory scrutiny.
• Reductions in staffing and funding at FDA and other federal agencies could cause delays in the development and approval of products.
• The business may be adversely affected by changes and uncertainty in the healthcare industry, including health care public policy developments.
• Failure to comply with the FDA's Quality System Regulation (QSR) or any applicable state equivalent could interrupt operations and harm potential product sales and operating results.
• If any products cause or contribute to a death or serious injury, or malfunction in certain ways, the company will be required to report under applicable medical device reporting regulations, potentially leading to corrective actions or enforcement.
• Healthcare reform initiatives and other administrative and legislative proposals may adversely affect the business, financial condition, results of operations, and cash flows in key markets.
• Inability to obtain and maintain patent protection for products could allow competitors to develop and commercialize similar or identical products, adversely affecting the ability to commercialize existing and future products.
• There is no guarantee that the company will be able to sell the QHS Notes, and any short-term sale may produce proceeds less than the market or stated value.

Future Outlook

Management projects a pivotal period of growth over the coming year, with major expansion of approved product lines across US and international markets. Confidence is amplified by the completion of two VIVO clinical studies in 2025, reinforcing VIVO's potential as a transformative approach to treating ventricular arrhythmias and capturing a dominant market share. However, the company also highlights substantial risks and uncertainties, including the need for additional financing, potential dilution, and the risk of delisting from NYSE American due to low stockholder equity.

Management Comments

• "Building on our impressive third-quarter results and a well-established pipeline, we believe that we are poised for a pivotal period of growth over the coming year."
• "We project a major expansion of both our approved product lines across the US and international markets."
• "Our confidence is further amplified by the completion of two VIVO clinical studies in 2025, which delivered powerful clinical evidence."
• "This data reinforces our position that VIVO represents a transformative approach to treating ventricular arrhythmias, potentially enabling us to capture a dominant share of a critically underserved market."

Industry Context

Catheter Precision operates in the cardiac electrophysiology market, a specialized segment of medical devices. Its products, VIVO (non-invasive 3D imaging for ventricular arrhythmias) and LockeT (suture retention device for venous closure), address specific needs in this field. The company's international expansion, particularly with CE Mark approval for LockeT and initial VIVO sales in Europe, indicates a strategy to tap into global demand for advanced EP solutions. The mention of an interview in EP Lab Digest suggests engagement with key opinion leaders and publications within the electrophysiology community, which is crucial for adoption in this specialized medical field.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks.

Stakeholder Impact

• Shareholders: Potential for significant dilution if new capital is raised; risk of delisting from NYSE American; potential for extreme market volatility. Positive revenue growth could lead to future value creation if financial stability is achieved.
• Employees: Continued operations and growth could secure employment, but financial instability and potential strategic shifts could create uncertainty.
• Customers (Hospitals, Physicians): Continued availability and expansion of innovative medical devices (VIVO, LockeT) to improve cardiac arrhythmia treatment.
• Suppliers: Continued demand for components, but potential risks if the company faces financial difficulties.
• Creditors: Exposure to risk due to the company's low cash position and going concern warning.

Next Steps

• Major expansion of approved product lines across the US and international markets.
• Continued sales activities for LockeT and VIVO outside the United States.
• Further clinical studies and publications for VIVO and LockeT.
• Addressing the need to raise additional funds to finance operations.
• Maintaining NYSE American listing requirements.

Key Dates

Recommendation

While Catheter Precision shows impressive revenue growth (135% in Q3) and a substantial reduction in its quarterly net loss, indicating strong product traction, the company faces critical financial challenges. The explicit "going concern" warning, low cash position, and risk of significant shareholder dilution or even delisting from the NYSE American present substantial downside risks. Investors should hold to monitor the company's ability to secure necessary financing and address its liquidity issues, as well as its progress in achieving profitability and expanding market share. The operational positives are compelling, but the financial risks are too significant to warrant a "buy" at this stage without clearer resolution of the funding situation.

Keywords

Catheter Precision, VTAK, medical device, cardiac electrophysiology, VIVO, LockeT, ventricular arrhythmias, suture retention device, Q3 2025 results, revenue growth, net loss, SEC filing, VIVO clinical studies, CE Mark, FDA clearance, medical technology